Accéder au contenu
Merck
  • Anticoagulant mechanism and platelet deaggregation property of a non-cytotoxic, acidic phospholipase A2 purified from Indian cobra (Naja naja) venom: inhibition of anticoagulant activity by low molecular weight heparin.

Anticoagulant mechanism and platelet deaggregation property of a non-cytotoxic, acidic phospholipase A2 purified from Indian cobra (Naja naja) venom: inhibition of anticoagulant activity by low molecular weight heparin.

Biochimie (2015-01-13)
Sumita Dutta, Debananda Gogoi, Ashis K Mukherjee
RÉSUMÉ

In the present study, anticoagulant and platelet modulating activities of an acidic phospholipase A2 (NnPLA2-I) purified from Indian cobra Naja naja venom was investigated. The NnPLA2-I displayed a mass of 15.2 kDa and 14,186.0 Da when analyzed by SDS-PAGE and MALDI-TOF-MS, respectively. Peptide mass fingerprinting analysis of the NnPLA2-I showed its significant similarity with phospholipase A2 enzymes purified from cobra venom. BLAST analysis of one tryptic peptide sequence of NnPLA2-I demonstrated putative conserved domains of the PLA2-like superfamily. The Km and Vmax values of NnPLA2-I toward hydrolysis of its most preferred substrate-phosphotidylcholine (PC)-were determined to be 0.72 mM and 29.3 μmol min(-1) mg(-1), respectively. The anticoagulant activity of NnPLA2-I was found to be higher than the anticoagulant activity of heparin/AT-III or warfarin. The histidine modifying reagent, monovalent and polyvalent antivenom differentially inhibited the catalytic and anticoagulant activities of NnPLA2-I. Low molecular weight heparin did not inhibit the catalytic and platelet deaggregation activity of NnPLA2-I, albeit its anticoagulant activity was significantly reduced. The NnPLA2-I showed a non-enzymatic, mixed inhibition of thrombin with a Ki value of 9.3 nM. Heparin significantly decreased, with an IC50 value of 15.23 mIU, the thrombin inhibitory activity of NnPLA2-I. The NnPLA2-I uniquely increased the amidolytic activity of FXa without influencing its prothrombin activating property. NnPLA2-I showed dose-dependent deaggregation of platelet rich plasma (PRP) and inhibited the collagen and thrombin-induced aggregation of PRP. However, deaggregation of washed platelets by NnPLA2-I demonstrated in presence of PC or platelet poor plasma. Alkylation of histidine residue of NnPLA2-I resulted in 95% and 21% reduction of its platelet deaggregation and platelet binding properties, respectively. NnPLA2-I did not show cytotoxicity against human glioblastoma U87MG cells, bactericidal or hemolytic activity. The future therapeutic application of NnPLA2-I for treatment and prevention of cardiovascular disorders is therefore suggested.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Acide trifluoroacétique, ReagentPlus®, 99%
Le tarif et la disponibilité ne sont pas disponibles actuellement. Contacter notre Service technique
Sigma-Aldrich
Acide trifluoroacétique, suitable for HPLC, ≥99.0%
Le tarif et la disponibilité ne sont pas disponibles actuellement. Contacter notre Service technique
Sigma-Aldrich
Acide trifluoroacétique, puriss. p.a., suitable for HPLC, ≥99.0% (GC)
Le tarif et la disponibilité ne sont pas disponibles actuellement. Contacter notre Service technique
Sigma-Aldrich
Acide trifluoroacétique, ≥99%, for protein sequencing
Le tarif et la disponibilité ne sont pas disponibles actuellement. Contacter notre Service technique
Sigma-Aldrich
4-nitroaniline, ≥99%
Le tarif et la disponibilité ne sont pas disponibles actuellement. Contacter notre Service technique
Supelco
Acide trifluoroacétique, analytical standard
Le tarif et la disponibilité ne sont pas disponibles actuellement. Contacter notre Service technique
Supelco
4-nitroaniline, analytical standard
Le tarif et la disponibilité ne sont pas disponibles actuellement. Contacter notre Service technique